title: Interleukin-6 and soluble interleukin-6 receptor suppress osteoclastic differentiation by inducing PGE(2) production in chondrocytes.
abstract: This study examined how interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6r) influence osteoclastic differentiation through the function of chondrocytes. Chondrocytes were cultured with or without IL-6 and/or sIL-6r in the presence or absence of NS398, a specific inhibitor of cyclooxygenase (COX)-2, for up to 28 days. Chondrocytes were also cultured with or without IL-6 and sIL-6r for 28 days, and the conditioned medium from cells cultured without IL-6 and sIL-6r was used to induce differentiation of RAW264.7 cells into osteoclast precursors. Osteoclastic differentiation was assessed by tartrate-resistant acid phosphatase (TRAP) staining. Expression of osteoprotegerin (OPG), receptor activator of NF-κB ligand (RANKL), COX-2, and prostaglandin E(2) (PGE(2)) increased in cells exposed to IL-6 and sIL-6r, whereas expression of macrophage colony-stimulating factor (M-CSF) and bone resorption-related enzymes decreased. NS398 blocked the stimulatory/suppressive effects of IL-6 and sIL-6r on the expression of OPG, RANKL, and M-CSF. Fewer TRAP-positive multinucleated cells were detected after treatment with conditioned medium from IL-6- and sIL-6r-treated chondrocytes than after treatment with conditioned medium from untreated chondrocytes. These results suggest that IL-6 and sIL-6r interfere with osteoclast function through the involvement of chondrocytes. Specifically, they appear to suppress the differentiation of osteoclast precursors into osteoclasts by inducing chondrocytic PGE(2) production, which, in turn, increases OPG secretion and decreases M-CSF secretion by chondrocytes.
authors.affiliation: Nihon University Graduate School of Dentistry, Tokyo, Japan. honda@dent.nihon-u.ac.jp
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Honda
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001862:Bone Resorption / Q000378:metabolism*; D024402:Carbonic Anhydrase II / Q000096:biosynthesis; D056657:Cathepsin K / Q000096:biosynthesis; D002454:Cell Differentiation; D002478:Cells, Cultured; D019902:Chondrocytes / Q000378:metabolism*; D051546:Cyclooxygenase 2 / Q000096:biosynthesis; D015232:Dinoprostone / Q000096:biosynthesis*; D015870:Gene Expression; D006801:Humans; D015850:Interleukin-6 / Q000502:physiology*; D016173:Macrophage Colony-Stimulating Factor / Q000096:biosynthesis; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis; D009578:Nitrobenzenes / Q000494:pharmacology; D010010:Osteoclasts / Q000166:cytology* / Q000378:metabolism; D053244:Osteoprotegerin / Q000096:biosynthesis; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis; D053245:RANK Ligand / Q000096:biosynthesis; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors / Q000502:physiology*; D013449:Sulfonamides / Q000494:pharmacology; D000093242:Interleukin-6 Inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D024402:Carbonic Anhydrase II; D056657:Cathepsin K; D051546:Cyclooxygenase 2; D015232:Dinoprostone; D015850:Interleukin-6; D016173:Macrophage Colony-Stimulating Factor; D020780:Matrix Metalloproteinase 9; D009578:Nitrobenzenes; D053244:Osteoprotegerin; D011451:Prostaglandin-Endoperoxide Synthases; D053245:RANK Ligand; D019947:Receptors, Interleukin-6; D013449:Sulfonamides; D000093242:Interleukin-6 Inhibitors; C080955:N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide